|Olmesartan||Angiotensin II antagonist|
|Amlodipine||Calcium channel blocker|
|ATC code||C09DB02 (WHO)|
The combination drug olmesartan/amlodipine (trade name Azor in the US) is an oral antihypertensive medication which combines two antihypertensive agents in a film-coated tablet. It contains amlodipine, a calcium channel blocker, and olmesartan medoxomil (trade name: Benicar), an angiotensin-2 receptor antagonist (ARB or A2A). The patent is held by Daiichi Sankyo Pharmaceuticals. Daiichi Sankyo filed a supplemental New Drug Application (sNDA) for Azor with the United States Food and Drug Administration on September 17, 2008. Azor has been studied in clinical trials; one test showed it reduced blood pressure during a 24-hour period and was well tolerated. Azor is available in different dose preparations: 5 mg/20 mg, 10 mg/20 mg,5 mg/40 mg and 10/40 mg's of amlodipine and olmesartan respectively. One investigation (which included doctors employed by Daiichi Sankyo) concluded that "From a pharmacokinetic perspective, the 2 drugs (amlodipine and olmesartan) are well suited to coadministration in a fixed-dose combination."
- PR Newswire (Sep 17, 2008). "Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial...". Reuters. Retrieved 2009-10-06.
- Joel M Neutel, MD & Henry Punzi, MD (June 2009 34(6)). "The AZTEC Trial: Amlodipine Besylate/Olmesartan Medoxomil (Azor)". P T. Pharmacy & Therapeutics. 34 (6): 318–21. PMC 2697919. PMID 19572050. Check date values in:
- Daiichi Sankyo, Inc (2009-10-06). "Information about Azor from the manufacturer". Daiichi Sankyo, Inc. Archived from the original on 29 September 2009. Retrieved 2009-10-06.
- Shashank Rohatagi, James Lee, Magdy Shenouda, MD, Stephen Haworth, MD, Mohinder Singh Bathala, Mark Allison, MD, Igor Rubets, Reinilde Heyrman, MD, Robert Noveck, MD and Daniel E. Salazar, FCP (2009-10-06). "PHARMACOKINETICS -- Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination". The Journal of Clinical Pharmacology. Retrieved 2009-10-06.